Competitor Analysis: MAGE-A-Targeted Immunotherapy
Competitor Analysis: MAGE-A-Targeted Immunotherapy
This Competitive Intelligence report analyzes the competitive field of MAGE-A-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
Melanoma Associated Antigens A (MAGE-A) are expressed in a variety of cancers of diverse histological origin and germinal cells. MAGE-A were the first human tumor-associated antigens identified at the molecular level. They belong to the larger family of cancer/testis antigens (CTA), whose expression is consistently detected in cancers of different histological origin and germinal cell. The MAGE-A sub-family includes 12 highly homologous genes located on chromosome Xq28. Specific gene products have been identified by immunohistochemistry in cancers of different histological origin, including high percentages of non-small cell lung cancers (NSCLC), bladder cancers, esophageal and head and neck cancers, and sarcomas. These antigens are also frequently expressed in triple negative breast cancers, myeloma, and Reed–Sternberg cells in Hodgkin’s disease, with the highest frequency being detected in synovial sarcoma.
Among healthy tissues, the expression of specific members of the family has been observed in spermatogonia, placenta, and fetal ovary. However, recently, MAGE-A1 and -A12 genes have been shown to be expressed in CNS. Preferential intracellular location may be different for different antigens, e.g., mostly cytoplasmic for MAGE-A1, -A3, and -A4, but mostly nuclear for MAGE-A10. Due to their relatively high tumor specificity, they represent attractive targets for active specific and adoptive cancer immunotherapies.
The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes/CTLs) and oncolytic viruses targeting melanoma associated antigen A (MAGE-A). In addition, the report lists company- and institution-specific R&D pipelines of MAGE-A-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report analyzes the competitive field of MAGE-A-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
Melanoma Associated Antigens A (MAGE-A) are expressed in a variety of cancers of diverse histological origin and germinal cells. MAGE-A were the first human tumor-associated antigens identified at the molecular level. They belong to the larger family of cancer/testis antigens (CTA), whose expression is consistently detected in cancers of different histological origin and germinal cell. The MAGE-A sub-family includes 12 highly homologous genes located on chromosome Xq28. Specific gene products have been identified by immunohistochemistry in cancers of different histological origin, including high percentages of non-small cell lung cancers (NSCLC), bladder cancers, esophageal and head and neck cancers, and sarcomas. These antigens are also frequently expressed in triple negative breast cancers, myeloma, and Reed–Sternberg cells in Hodgkin’s disease, with the highest frequency being detected in synovial sarcoma.
Among healthy tissues, the expression of specific members of the family has been observed in spermatogonia, placenta, and fetal ovary. However, recently, MAGE-A1 and -A12 genes have been shown to be expressed in CNS. Preferential intracellular location may be different for different antigens, e.g., mostly cytoplasmic for MAGE-A1, -A3, and -A4, but mostly nuclear for MAGE-A10. Due to their relatively high tumor specificity, they represent attractive targets for active specific and adoptive cancer immunotherapies.
The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes/CTLs) and oncolytic viruses targeting melanoma associated antigen A (MAGE-A). In addition, the report lists company- and institution-specific R&D pipelines of MAGE-A-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) MAGE-A-TARGETED IMMUNOTHERAPY:
MAGE-A1
MAGE-A3
MAGE-A4
MAGE-A6
MAGE-A10
MAGE-A12
2) CORPORATE & INSTITUTIONAL MAGE-A IMMUNOTHERAPY R&D PIPELINES
MAGE-A1
MAGE-A3
MAGE-A4
MAGE-A6
MAGE-A10
MAGE-A12
2) CORPORATE & INSTITUTIONAL MAGE-A IMMUNOTHERAPY R&D PIPELINES
